I have just been doing a quick review ot theThomson Reuters Q4...

I have just been doing a quick review ot theThomson Reuters Q4 2010 review of the five most promising drugs entering phase 3 trials to see how we fared with our progress compared with the others. Remember we are talking about the progress of the trials over 18 months.

1) V212 Merck and Co
Still in Phase 3 trials....can't track down an end date.

2) Chemrivax Dengue Sanofi Pasteur
As of 6 May 2012 studying efficacy of its new Dengue vaccine which is expected in 2015

3) AN2690 Anacor
Phase 3 report due in 2nd half of 2012

4) IMA 901 Immatics
First overall results expected in 2013

5) ArTiMist. EMS
Phase 3 underway to be completed?.... My guess is last Q 2012

So all in all compared with our 4 peers who made the same list that we did just 18 months ago we ain't doing too bad are we?could we do better?....most certainly.

Worth thinking about.. isn't it?

kippax